Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

SELLAS Life Sciences Group, Inc. (SLS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.3400+0.0100 (+0.30%)
At close: 04:00PM EDT
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • c
    ctrl+p_QE.exe
    Sellas on twitter just now:
    Once the @US_FDA approves, Phase 4 is often used to gather information about the drug's impact in populations and side effects with long-term use. The treatment is monitored for a lengthy period to assess patient safety, quality of life and cost-effectiveness. $SLS
    Bullish
  • j
    jason
    So what’s the tipping point? At what value do people start thinking this has potential? $4? $5? There will be a point where this just takes off, and hopefully stays there this time.
  • J
    John
    Yes I am long and holding until FDA approval , since we should be sitting in the teens right now, we could run to $15.00 in the next 30 days.

    Undervalued by at least 450m on the market cap right now since this is a phase 3 asset with expanded access outside the trials
    Bullish
  • C
    Cured
    Gps symposium focused on commercialization. Corp Presentation sizes up the market - $200m in Prj rev for AML Cr2 and 4/5x that for CR1, ASCT.
    $200M to $800M in Rev - Big Pharma will Pay billions for that much revenue and SLS only trades for $60M
    Bullish
  • E
    ExPharmaGuy
    Short sellers are not happy with the increase in price. The real risk is that the Phase 3 data does not achieve statistical significance, meanwhile top companies like Citadel and Vanguard are buying more. Another impetus is Dr. #$%$arjian's request for expanded access which means he is seeing something positive in his patients. They also appointed a highly experienced pharma exec for their board. I continue to accumulate.
  • r
    robert
    Who is more credible?
    The new Member of SLS Board or
    the Bashers on this Yahoo Board?
  • W
    Wali
    I welcome the new highs and push to 4s
    Bullish
  • g
    greg
    IMP; Certainly a small % short outstanding, but nearly 1 M shares have to be repurchased before too long. The minuscule volume will be ratcheting the squeeze pressure on a daily basis going forward approaching the FDA Approval.
  • C
    Cured
    I am seeing drugs with Expanded Access Programs have FDA approval rates higher than 95% - can any of you confirm this? Really Seriously, though is a quarter or two a long time to wait for a 2,500% Return on an Investment. The first GPS FDA Green light for AML patients Incoming.
  • H
    HotBlonde
    I bought a few shares
  • C
    Cured
    Cantor Analyst “Even in the initial niche target population of AML patients after second complete remission, “we project the peak sales to be about $200-million,” she added.

    “Overtime, we think GPS has the potential to broaden into AML patients after first complete remission, as well as in other indications with combinations,” Ms. Watsek said.
    Bullish
  • C
    Cured
    Gps Symposium focused on commercializing the first FDA Approved Immunotherapy for AML patients.
    The Corp Prez sizes up the market - $200m in proj rev for AML Cr2, then 4 to 5x that for CR1, and ASCT.
    $200M to $800M in Rev - Big Pharma will Pay billions for that much revenue and SLS only trades for $60M

    All the short Fud and Market manipulation makes sense when you understand how oversold and under valued this equity is.
    Bullish
  • T
    Troy
    @ cured. Legit question. If large bio thinks there’s even a remote possibility of these type of returns why haven’t they made an offer to buy here before it goes through the roof? Thanks
  • T
    Troy
    Someone buying in size this morning 🤔
    Bullish
  • C
    Cured
    Gps Symposium focused on commercializing the first FDA Approved Immunotherapy for AML patients.
    Corp prez sizes up the market: $200m in proj rev for AML Cr2, then 4 to 5x that for CR1, and ASCT.
    $200M to $800M in Rev - Big Pharma will Pay billions for that much revenue and SLS only trades for $60M

    All the short Fud and Market manipulation makes sense when you understand how oversold and under valued this equity is.
    SELLAS is a late-stage immune-oncology company that is focused on novel cancer vaccines. The lead drug candidate, galinpepimut-S (GPS), is a peptide vaccine that target Wilms tumor 1 and is in a Phase 3 trial for acute myeloid leukemia (AML).
    Cantor Fitz analyst
    Even in the initial niche target population of AML patients after second complete remission, “we project the peak sales to be about $200-million,” she added.

    “Overtime, we think GPS has the potential to broaden into AML patients after first complete remission, as well as in other indications with combinations,” Ms. Watsek said.
    Bullish
  • C
    Cured
    Pretty Simple - SlS is worth more than it trades for. Inefficient markets allow manipulated pricing for a period of time, until they don't. That type of comeuppance usually occurs when you have a FDA Approval looming.
  • M
    MoneyCalls
    I like this stock. Hoping we get a market correction so I can load up. I have some so if we keep going up that will be fine too. Didn't someone say there was a press release or news soon?
    Bullish
  • j
    james
    $4B Buyout for an AML Agent combined with Venetoclax and Az - Axed. GFH009 P1 results to date are 4x as good as i-mabs cd47 agent - Intriguing
    https://endpts.com/abbvie-calls-off-phi-trial-for-i-mabs-cd47-days-after-zai-lab-shelves-its-own-program/
    Bullish
  • J
    John
    Looking forward to Sept 15th symposium
    Upward Onward.
    PT $25.00
    Bullish
  • M
    MoneyCalls
    Fda approval coming
    Bullish
Advertisement
Advertisement